Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of August 29, 2026, CYTK trades at $72.50 with a market cap of $10.83B and a P/E ratio of -9.98. CYTK moved -7.36% today. Year to date, CYTK is +16.78%; over the trailing twelve months it is +93.01%. Its 52-week range spans $29.31 to $88.31. Analyst consensus is strong buy with an average price target of $111.80. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CYTK combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $72.50 |
| Market Cap | $10.83B |
| P/E Ratio | -9.98 |
| EPS | $-7.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $88.31 |
| 52-Week Low | $29.31 |
| Volume | 1.18M |
| Avg Volume | 0 |
| Revenue (TTM) | $67.67M |
| Net Income | $-894.00M |
| Gross Margin | 0.00% |
17 analysts cover CYTK: 0 strong buy, 16 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $111.80.